Gyre Therapeutics Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -37.9% | -45.2% | +3.7% | +216.1% | -21.1% | -3.8% | -41.3% | +52.3% | +37.5% | +7.6% | +32.5% | |
| – | -36.5% | -45.4% | +4.2% | +217.0% | -22.5% | -6.8% | -42.5% | -3.5% | +15.2% | +13.2% | +58.0% | |
| – | -48.4% | -64.7% | +41.0% | +115.7% | -50.8% | +97.5% | +46.1% | -43.2% | +33.1% | -64.7% | +213.8% | |
| – | -69.7% | -47.5% | +90.1% | +270.3% | -36.0% | +3.2% | -41.0% | -46.3% | +33.1% | -20.4% | +96.6% | |
| – | +248.9% | -93.7% | -22.6% | – | – | -77.9% | -45.1% | +758.9% | +7.8% | +73.1% | +26.7% | |
| – | – | -42.4% | -72.7% | – | – | – | +89,711.8% | +581.6% | -30.1% | +48.0% | +60.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -43.1% | -8.5% | +0.4% | +177.2% | |
| – | +1,207.3% | -42.2% | -60.3% | -43.1% | +507.4% | -37.9% | -22.4% | -14.0% | +718.4% | -73.7% | -11.7% | |
| – | +1,195.7% | -41.8% | -60.2% | -45.1% | +501.9% | -38.4% | -20.4% | -13.6% | +63.8% | -2.6% | -6.3% | |
| – | – | -42.5% | -73.8% | – | – | +37.3% | +198.2% | -75.1% | -57.3% | +239.5% | -10.8% | |
| – | +131.9% | -10.9% | -10.8% | +67.1% | +242.9% | +38.6% | +8.2% | -98.1% | +191.0% | -69.6% | +14.8% | |
| – | -71.2% | -48.9% | +91.5% | +289.8% | -43.0% | +11.3% | -46.0% | +3.5% | -137.2% | – | +67.5% | |
| – | – | – | – | – | – | – | – | – | -950.7% | – | – | |
| – | -8.2% | +163.8% | +339.6% | +227.5% | +7.1% | +59.8% | +59.8% | +147.0% | -13.0% | +55.4% | +0.9% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.